Compare · DXCM vs LMAT
DXCM vs LMAT
Side-by-side comparison of DexCom Inc. (DXCM) and LeMaitre Vascular Inc. (LMAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and LMAT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $22.98B, about 9.2x LMAT ($2.51B).
- DXCM has been more active in the news (8 items in the past 4 weeks vs 6 for LMAT).
- DXCM has more recent analyst coverage (25 ratings vs 16 for LMAT).
- Company
- DexCom Inc.
- LeMaitre Vascular Inc.
- Price
- $59.53+3.39%
- $109.56+2.25%
- Market cap
- $22.98B
- $2.51B
- 1M return
- -
- +0.21%
- 1Y return
- -
- +21.18%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2006
- News (4w)
- 8
- 6
- Recent ratings
- 25
- 16
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
LeMaitre Vascular Inc.
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes, which cut valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular patches, which are used for closure of vessels after surgical intervention; closure systems to attach vessels to one another with titanium clips instead of sutures; and surgical glue. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Latest DXCM
- SEC Form 10-Q filed by DexCom Inc.
- DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Dexcom Reports First Quarter 2026 Financial Results
- Why Medtech Giants Are Quietly Paying Up for AI Diagnostics
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
Latest LMAT
- Director Pellegrino Joseph P Jr exercised 2,941 shares at a strike of $35.48, increasing direct ownership by 24% to 15,021 units (SEC Form 4)
- LeMaitre Will Announce First Quarter 2026 Earnings Results on May 5, 2026
- SEC Form DEFA14A filed by LeMaitre Vascular Inc.
- SEC Form DEF 14A filed by LeMaitre Vascular Inc.
- LeMaitre Vascular Inc. filed SEC Form 8-K: Leadership Update
- LeMaitre to Present at the 25th Annual Needham Virtual Healthcare Conference
- SEC Form 4 filed by Shadan Martha
- SEC Form 4 filed by Ross Bridget A
- SEC Form 4 filed by O'Connor John James
- SEC Form 4 filed by Roush John A